Lyme borreliosis is caused by the spirochete Borrelia burgdorferi, which is transmitted by Ixodes ticks and can result in musculoskeletal, cardiac, and neurologic diseases (20) . Various animal models, including rats, hamsters, and mice, have been developed to study experimental Lyme disease (5, 6, 14) . The C3H/He mouse is a superior model since mature, immunocompetent animals develop arthritis and carditis when challenged with B. burgdorferi, partially mimicking human disease (5) . By 14 days after intradermal infection with small numbers of spirochetes, all mice develop polyarthritis and carditis (4) . As in humans, the disease regresses and is exacerbated over the course of several months, and spirochetes may be cultured from the blood, spleen, skin, and other organs of the mice up to 1 year after infection (7) . Three (12) . Furthermore, passive administration of polyclonal and monoclonal antibodies to OspA, as well as polyclonal anti-B. burgdorferi serum, protects both immunocompetent and scid mice from infection (12, 18) . OspB is also located on the surface of the spirochete; the OspB gene is on the same 49-kb linear plasmid as OspA, and both genes are transcribed from a common promoter (8) . In * Corresponding author.
addition, a 41-kDa flagellar protein named flagellin has been identified, cloned, and sequenced (2, 13) . Antibodies to flagellin appear early in both human and animal infections, whereas antibodies to OspA and OspB appear early in murine infections and later in human disease (5, 10) . The roles of these antibodies in protective immunity are unclear, although in a recent review it has been suggested that monoclonal and polyclonal antibodies to flagellin do not protect scid mice from infection and that monoclonal antibodies to OspB partially delay the development of infection and disease in scid mice (19) . The purpose of this study was to determine whether OspA, OspB, and flagellin B. burgdorferi proteins evoke protective immunity. position with respect to the promoter, was used to amplify OspB-B31. The oligonucleotide primers used for amplification were based on the known nucleotide sequences of OspA, OspB, and flagellin and were flanked by restriction enzyme digestion sites to facilitate cloning and expression (8, 13) . The polymerase chain reaction-amplified DNA segments were isolated by agarose gel electrophoresis and purified by electroelution with a DEAE membrane. The purified DNA was digested with EcoRI and BamHI, and the genes for OspA-N40, OspB-B31, and flagellin-N40 were ligated into plasmid pGEX-2T (Pharmacia) in frame with the glutathione transferase gene. pGEX-2T contains the glutathione transferase gene of Schistosoma japonicum under control of the tac promoter, which is inducible with isopropyl-3-D-thiogalactopyranoside (IPTG (12) .
MATERIALS AND METHODS

Mice
Absorption of rabbit anti-B. burgdorferi serum with recombinant OspA and OspB. Rabbit anti-B. burgdorferi N40 serum was prepared as previously described (12) . A 2-mg sample of recombinant OspA fusion protein, OspB fusion protein, or glutathione transferase was bound to Sepharose 4B by CNBr activation. Specifically, 0.8 g of CNBr-activated Sepharose 4B (Pharmacia catalog no. 17-0430-01) was washed with 200 ml of 1 mM HCI and then equilibrated with coupling buffer (0.1 M NaHCO3-0.5 M NaCl, pH 8.3). A 2-mg sample of recombinant antigen in coupling buffer was added to the gel, and the mixture was shaken end over end at room temperature for 2 h. The gel was washed twice with coupling buffer, and then 4 ml of ethanolamine (pH 9.0) was added to the gel, which was then incubated for 2 h to block any unbound sites. The gel was washed three times with 50 ml of 0.1 M sodium acetate-0.5 M NaCl, pH 4.0, and then equilibrated in PBS and stored at 4°C in PBS with 0.01% sodium azide. A 5-ml sample of rabbit anti-B. burgdorferi N40 serum was passed over the OspA column twice to remove antibodies to OspA. The serum was diluted 1:50 (1.4 mg/ml) for immunization experiments and 1:100 to 1:10,000 for immunoblots. Serum which had been passed over the OspA column was then passed over an OspB column four times to remove antibodies to OspB. This serum was also diluted to a concentration of 1.4 mg/ml for passive immunization. As a control, serum was passed over the glutathione column in a similar fashion.
Vaccination and challenge of C3H mice. OspA or glutathione transferase column. The band at 57 kDa represents the recombinant OspA fusion protein, and the band above 57 kDa is an E. coli product that is reactive with the rabbit antiserum. Lanes 1 through 3, antisera (1:100, 1:1,000, and 1:10,000, respectively) passed over a glutathione transferase column; lanes 4 through 6, antisera (1:100, 1:1,000, and 1:10,000. respectively) passed over an OspA column. gel was determined by the method developed by Bradford (9) . The protein was probed with a 1:100 dilution of an OspB-N40 monoclonal antibody, designated OspB Mab 7 B10.36 and produced at Yale, or stained with Coomassie brilliant blue. The bands which showed binding to the OspB monoclonal antibody were excised from the membrane stained with Coomassie brilliant blue and directly sequenced at the N terminus at the Yale Protein Chemistry Laboratory.
RESULTS
To determine whether antibodies to proteins other than OspA play roles in protective immunity to spirochete infection, rabbit anti-B. burgdorferi serum was twice passed over a recombinant OspA column. The removal of anti-OspA antibodies appeared to be complete, since the eluted serum showed no binding with the recombinant OspA fusion protein in the immunoblot (Fig. 1) anti-B. burgdorferi serum which had been passed over a glutathione column. To determine whether antibodies to proteins other than OspA and OspB are involved in protective immunity, anti-B. burgdorferi serum was passed over both an OspA and an OspB column. The residual sera did not react with OspA or OspB on the immunoblot (data not shown). Mice passively immunized with the residual sera developed infections when challenged with 104 spirochetes, suggesting that OspA and OspB are major determinants in protection. Previous work has indicated that mice vaccinated with OspA are protected from challenge with an intradermal inoculation of 104 spirochetes (12) . To determine whether the protective effect of OspA was dose dependent, the studies were repeated with a larger dose of spirochetes. Mice were protected against challenge with 104 spirochetes, but this protective effect was removed by challenging the mice with an inoculum of 107 organisms (see Table 2 ). Even at this challenge dose, the degrees of periarticular edema and synovial proliferation seen on microscopic examination of the joints were less severe in vaccinated mice (grade 1) than in control animals (grade 3).
To determine the roles of OspB and flagellin in protective immunity, animals were actively immunized with the recombinant proteins. Mice immunized with recombinant OspB made antibodies to OspB which were detectable on immunoblot at a dilution of 1:5,000 (Fig. 2) . Antibodies in sera from mice immunized with recombinant OspB did not bind to native OspA on immunoblot, suggesting that the majority of Osp antibodies are not cross-reactive. This corroborates our previous results, which showed that the sera from mice immunized with recombinant OspA bound native OspA but not native OspB on immunoblot (12 Met-X-Leu-Leu-Ile-Gly-Phe-Ala-Leu-Ala-Leu-Ala-Leu-IleGly-X-Ala-Gln-Lys-Ala-Glu-Ser-Ile. Neither the 34-kDa nor the 17-kDa Borrelia protein was amenable to direct sequencing, suggesting that the proteins were blocked at the amino terminus. Mice subcutaneously immunized with the cell extract containing 10 jig of recombinant flagellin produced antibodies to flagellin which could be detected at a dilution of 1:6,000 on immunoblot.
Mice immunized with OspB were challenged intradermally with 104, 103, or 102 B. burgdorferi B31 or N40 spirochetes and evaluated for protection ( Table 2 ). The animals were protected from infection and disease in a (12) . Furthermore, there is some degree of cross protection, since animals immunized with OspA from B. burgdorferi N40 are protected against challenge with three strains of the spirochete, namely, N40, B31, and CD16 (12) . The present report shows that vaccination with OspB from strain B31 is sufficient to protect against challenge with 103 B31 spirochetes but not against 103 N40 spirochetes, suggesting that OspB protection may be somewhat strain specific. Indeed, initial sequencing data indicate that the OspB-N40 gene differs from the OspB-B31 gene by at least nine nucleotides, which corresponds to six amino acid differences (11). It is not known whether strains B31 and N40 are in the same taxonomic group; however, OspA and OspB from both strains of the spirochete migrate at identical positions on SDS-PAGE, and the nucleotide sequences of the OspA-B31 and OspA-N40 genes are highly conserved (12) . Once recombinant OspB-N40 is obtained, experiments will determine whether vaccination with OspB-N40 protects mice from challenge with B. burgdorferi N40.
It is also possible that the degrees of virulence of the N40 and B31 spirochetes may play roles in the lack of cross protection. B. burgdorferi N40 is more virulent than B31, as the control animals challenged with N40 generally have more disease manifestations. It can be hypothesized that the immune response to OspB is able to protect against a moderately virulent strain of Borrelia but not against a highly pathogenic organism. Further work with different strains of B. burgdorferi which are found to be infectious in the C3H mouse will address this question. It must also be determined whether the dose of spirochetes delivered via an intradermal injection is qualitatively and quantitatively different from that administered by a tick bite. If the number of spirochetes introduced by a tick bite is fewer than 1,000 organisms and no qualitative differences exist in tick inoculations, then OspA, OspB, or hybrid molecules would afford full protection. Overall, the present experiments indicate that OspA and OspB are both vaccine candidates for Lyme disease.
